JMP Securities analyst Silvan Tuerkcan lowered the firm’s price target on Terns Pharmaceuticals to $15 from $17 and keeps an Outperform rating on the shares. Terns’ work in Chronic Myeloid Leukemia with TERN-701 is “promising,” and point to data in 2H24 that may already include results of second-line patients, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TERN:
- Terns Pharmaceuticals reports Q4 EPS (29c), consensus (29c)
- Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
- Terns Pharmaceuticals receives orphan drug designation for TERN-701 from FDA
- Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
- Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
